TW202237601A - 介白素-1受體相關激酶(irak)降解物及其用途 - Google Patents

介白素-1受體相關激酶(irak)降解物及其用途 Download PDF

Info

Publication number
TW202237601A
TW202237601A TW110146161A TW110146161A TW202237601A TW 202237601 A TW202237601 A TW 202237601A TW 110146161 A TW110146161 A TW 110146161A TW 110146161 A TW110146161 A TW 110146161A TW 202237601 A TW202237601 A TW 202237601A
Authority
TW
Taiwan
Prior art keywords
alkyl
ring
membered
optionally substituted
nitrogen
Prior art date
Application number
TW110146161A
Other languages
English (en)
Chinese (zh)
Inventor
孝章 鄭
瀟 朱
Original Assignee
美商凱麥拉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商凱麥拉醫療公司 filed Critical 美商凱麥拉醫療公司
Publication of TW202237601A publication Critical patent/TW202237601A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW110146161A 2020-12-09 2021-12-09 介白素-1受體相關激酶(irak)降解物及其用途 TW202237601A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063123330P 2020-12-09 2020-12-09
US63/123,330 2020-12-09

Publications (1)

Publication Number Publication Date
TW202237601A true TW202237601A (zh) 2022-10-01

Family

ID=81973811

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110146161A TW202237601A (zh) 2020-12-09 2021-12-09 介白素-1受體相關激酶(irak)降解物及其用途

Country Status (13)

Country Link
US (2) US20230096599A1 (enExample)
EP (1) EP4259128A4 (enExample)
JP (1) JP7832945B2 (enExample)
KR (1) KR20230130179A (enExample)
CN (1) CN116669722A (enExample)
AR (1) AR124294A1 (enExample)
AU (1) AU2021396308A1 (enExample)
CA (1) CA3200608A1 (enExample)
CO (1) CO2023006818A2 (enExample)
IL (1) IL303458A (enExample)
MX (1) MX2023006719A (enExample)
TW (1) TW202237601A (enExample)
WO (1) WO2022125790A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
KR20220145325A (ko) 2019-12-17 2022-10-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
CN116867758A (zh) * 2020-12-30 2023-10-10 凯麦拉医疗公司 Irak降解剂和其用途
CA3243560A1 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Iraqi Degradation Agents and Their Uses
WO2024020084A1 (en) * 2022-07-20 2024-01-25 Bristol-Myers Squibb Company Heteroaryl compounds as ligand directed degraders of irak4
IL325910A (en) * 2023-07-13 2026-03-01 Increland Aromatic compound, pharmaceutical preparation comprising the same, and use thereof
CN121816348A (zh) 2023-08-11 2026-04-07 深圳众格生物科技有限公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
WO2025051160A1 (zh) * 2023-09-08 2025-03-13 北京华益健康药物研究中心 用于治疗或预防冠状病毒感染的3cl蛋白酶抑制剂及其用途
CN120025333A (zh) * 2023-11-22 2025-05-23 广东东阳光药业股份有限公司 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途
WO2025168131A1 (zh) * 2024-02-08 2025-08-14 清华大学 一种多靶降解剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6126131B2 (ja) * 2012-01-10 2017-05-10 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
CA2988461A1 (en) * 2015-06-26 2016-12-29 Dana-Farber Cancer Institute, Inc. Fused bicyclic pyrimidine derivatives and uses thereof
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3445765A4 (en) * 2016-04-22 2019-09-18 Dana Farber Cancer Institute, Inc. DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
EP3710443A1 (en) * 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2020010227A1 (en) * 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CA3119773A1 (en) * 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021053555A1 (en) * 2019-09-16 2021-03-25 Novartis Ag Glue degraders and methods of use thereof
KR20230005160A (ko) * 2020-03-19 2023-01-09 카이메라 쎄라퓨틱스 인코포레이티드 Mdm2 분해제 및 이의 용도

Also Published As

Publication number Publication date
EP4259128A4 (en) 2025-04-30
AR124294A1 (es) 2023-03-15
US20250375526A1 (en) 2025-12-11
CO2023006818A2 (es) 2023-07-10
AU2021396308A1 (en) 2023-06-22
MX2023006719A (es) 2023-06-23
CN116669722A (zh) 2023-08-29
IL303458A (en) 2023-08-01
JP7832945B2 (ja) 2026-03-18
JP2023552827A (ja) 2023-12-19
EP4259128A1 (en) 2023-10-18
WO2022125790A1 (en) 2022-06-16
US20230096599A1 (en) 2023-03-30
CA3200608A1 (en) 2022-06-16
KR20230130179A (ko) 2023-09-11
AU2021396308A9 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
US11591332B2 (en) IRAK degraders and uses thereof
US12569485B2 (en) SMARCA inhibitors and uses thereof
JP7832945B2 (ja) Ｉｒａｋ分解剤およびそれらの使用
US20230089916A1 (en) Irak degraders and uses thereof
EP4271664A1 (en) Irak degraders and uses thereof
WO2021158634A1 (en) Irak degraders and uses thereof
US20220324880A1 (en) Smarca inhibitors and uses thereof
WO2020251969A1 (en) Smarca degraders and uses thereof
TW202136251A (zh) Irak降解劑及其用途
KR20230005160A (ko) Mdm2 분해제 및 이의 용도
JP2023509394A (ja) Ｓｍａｒｃａ分解剤およびそれらの使用
WO2022125804A1 (en) Smarca degraders and uses thereof
US20240383868A1 (en) Smarca degraders and uses thereof
WO2023220425A1 (en) Bcl-xl/bcl-2 degraders and uses thereof